Mechanism of hepatotoxicity of first-line tyrosine kinase inhibitors: Gefitinib and afatinib
Authors:
- 1 June 2021
- journal article
- research article
- Published by Elsevier in Toxicology Letters
- Vol. 343, 1-10
Abstract
No abstract availableKeywords
Funding Information
- Six Talent Climax Foundation of Jiangsu
This publication has 56 references indexed in Scilit:
- A Novel, Reliable Method for Repeated Blood Collection from Aquarium FishZebrafish, 2013
- Slc39a7/zip7 Plays a Critical Role in Development and Zinc Homeostasis in ZebrafishPLOS ONE, 2012
- Clinical Pharmacokinetics of Tyrosine Kinase InhibitorsClinical Pharmacokinetics, 2011
- A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GISTCancer Treatment Reviews, 2011
- Evidence for a core gut microbiota in the zebrafishThe ISME Journal, 2011
- Identification and developmental expression of the full complement of Cytochrome P450 genes in ZebrafishBMC Genomics, 2010
- Metabolism considerations for kinase inhibitors in cancer treatmentExpert Opinion on Drug Metabolism & Toxicology, 2010
- Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Gefitinib: Implications for Pulmonary and Hepatic ToxicitiesChemical Research in Toxicology, 2009
- Requirement of vasculogenesis and blood circulation in late stages of liver growth in zebrafishBMC Developmental Biology, 2008
- Drug-Induced Liver DisordersDrug Safety, 2001